-+ 0.00%
-+ 0.00%
-+ 0.00%
Cantargia Names IL-17 as Second Target for Preclinical CAN14 Antibody
Share
Listen to the news
Cantargia Names IL-17 as Second Target for Preclinical CAN14 Antibody
  • Cantargia identified IL-17 as the second target for CAN14, its bispecific antibody in preclinical development for chronic inflammatory diseases.
  • CAN14 is designed to combine IL1RAP-mediated pathway blockade with IL-17 inhibition to address multiple drivers of inflammation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cantargia AB published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending